Rafael Holdings, Inc. Class B Common Stock (RFL) Stock Price

RFLStock
$1.39+4.51%52W
Market Cap$72.28M
P/E—
PEG Ratio—
Div yield—
Beta0.67

RFL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-1.31%
Price vs S&P 500 (4W)-29.17%
VGM Score40.77

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
RFLRafael Holdings, Inc. Class B Common Stock
DDC73.8x33.9%95.1%—$1.39
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings is a biotechnology company with a lead asset, Trappsol Cyclo, in Phase 3 trials for Niemann-Pick Disease Type C1. The company pursues regulatory approval and commercialization while maintaining a diversified portfolio of clinical and early-stage pharmaceutical and medical device investments. Operations span three segments—healthcare, infusion technology, and real estate—with locations in the United States and Israel.